Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01584843
First received: April 23, 2012
Last updated: July 3, 2014
Last verified: July 2014
  Purpose

Primary objective is to evaluate the efficacy of single-dose treatment with GSK1358820 compared with non-treatment in patients with strabismus based on angles of strabismus in the primary position.


Condition Intervention Phase
Strabismus
Drug: GSK1358820
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Evaluator-masked, Parallel-group, Non-treatment-controlled Study Followed by an Open-label Study to Evaluate Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Change From Baseline in Strabismus Angle Prism Dioptre (PD) in the Primary Position at Week 4 of the FTP in Observed Cases (OC) [ Time Frame: Baseline and Week 4 of the FTP ] [ Designated as safety issue: No ]
    The strabismus angle in the primary position was measured using the alternative prism cover test (APCT). The strabismus angle was evaluated as the mean value of the distant-view strabismus angle (measured at a distance of 5 meters [m]) and the near-view strabismus angle (measured at a distance of 33 centimeters [cm]). Every participant's evaluation was performed in the same affected eye (left or right) throughout the study period. Change from Baseline was calculated as the value at Week 4 minus the value at Baseline.


Secondary Outcome Measures:
  • Change From Baseline in the Strabismus Angle Prism Dioptre (PD) in the Primary Position at Week 1 After the Initial Injection of the FTP in Observed Cases (OC) [ Time Frame: Baseline and Week 1 of the FTP ] [ Designated as safety issue: No ]
    The strabismus angle in the primary position was measured using the APCT. The strabismus angle was evaluated as the mean value of the distant-view strabismus angle (measured at a distance of 5 m) and the near-view strabismus angle (measured at a distance of 33 cm). Every participant's evaluation was performed in the same affected eye (left or right) throughout the study period. Change from Baseline was calculated as the value at Week 1minus the value at Baseline.

  • Change From Baseline in the Strabismus Angle PD in the Primary Position at Weeks 1, 4, 8, 12, 16, 20, and 24 After the Final Injection of the FTP [ Time Frame: Baseline and Weeks 1, 4, 8, 12, 16, 20, and 24 after the final injection of the FTP ] [ Designated as safety issue: No ]
    The strabismus angle in the primary position was measured using the APCT. The strabismus angle was evaluated as the mean value of the distant-view strabismus angle (measured at a distance of 5 m) and the near-view strabismus angle (measured at a distance of 33 cm). Every participant's evaluation was performed in the same affected eye (left or right) throughout the study period. The values were summarized for the observed cases for the change in the strabismus angle in the primary position from Baseline at Weeks 1, 4, 8, 12, 16, 20, and 24 (before reinjection of the second treatment period if applicable) after the final injection of the FTP (after randomization in the non-treatment groups). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

  • Change From Baseline in the Strabismus Angle PD in the Primary Position at Weeks 1, 4, 8, 12, 16, 20, and 24 of the Second Treatment Period (STP) [ Time Frame: Baseline and Weeks 1, 4, 8, 12, 16, 20, and 24 of the STP (up to Study Week 52) ] [ Designated as safety issue: No ]
    The strabismus angle in the primary position was measured using the APCT. The strabismus angle was evaluated as the mean value of the distant-view strabismus angle (measured at a distance of 5 m) and the near-view strabismus angle (measured at a distance of 33 cm). Every participant's evaluation was performed in the same affected eye (left or right) throughout the study period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

  • Absolute Strabismus Angle in the Primary Position at Weeks 1 and 4 of the FTP [ Time Frame: Weeks 1 and 4 of the FTP ] [ Designated as safety issue: No ]
    The strabismus angle in the primary position was measured using the APCT. The strabismus angle was evaluated as the mean value of the distant-view strabismus angle (measured at a distance of 5 m) and the near-view strabismus angle (measured at a distance of 33 cm). Every participant's evaluation was performed in the same affected eye (left or right) throughout the study period. The absolute values of the strabismus angle in the primary position at Week 1 and Week 4 of the FTP were summarized for observed cases without imputation of missing values.

  • Absolute Strabismus Angle in the Primary Position at Weeks 1, 4, 8, 12, 16, 20, and 24 After the Final Injection of the FTP [ Time Frame: Weeks 1, 4, 8, 12, 16, 20, and 24 after the final injection of the FTP ] [ Designated as safety issue: No ]
    The strabismus angle in the primary position was measured using the APCT. The strabismus angle was evaluated as the mean value of the distant-view strabismus angle (measured at a distance of 5 m) and the near-view strabismus angle (measured at a distance of 33 cm). Every participant's evaluation was performed in the same affected eye (left or right) throughout the study period. The absolute values of the strabismus angle in the primary position were summarized for observed cases at Weeks 1, 4, 8, 12, 16, 20, and 24 (before reinjection of the second treatment period if applicable) after the final injection of the FTP (after randomization in the non-treatment groups).

  • Absolute Strabismus Angle in the Primary Position at Weeks 1, 4, 8, 12, 16, 20, and 24 of the STP [ Time Frame: Weeks 1, 4, 8, 12, 16, 20, and 24 of the STP (up to Study Week 52) ] [ Designated as safety issue: No ]
    The strabismus angle in the primary position was measured using the APCT. The strabismus angle was evaluated as the mean value of the distant-view strabismus angle (measured at a distance of 5 m) and the near-view strabismus angle (measured at a distance of 33 cm). Every participant's evaluation was performed in the same affected eye (left or right) throughout the study period.

  • Percent Change From Baseline in the Strabismus Angle in the Primary Position at Week 1 and Week 4 in Observed Cases (OC) of the FTP [ Time Frame: Baseline and Weeks 1 and 4 of the FTP ] [ Designated as safety issue: No ]
    The strabismus angle in the primary position was measured using the APCT. The strabismus angle was evaluated as the mean value of the distant-view strabismus angle (measured at a distance of 5 m) and the near-view strabismus angle (measured at a distance of 33 cm). Every participant's evaluation was performed in the same affected eye (left or right) throughout the study period. The values were summarized for observed cases for the percent change from Baseline in the strabismus angle in the primary position at Week 1and Week 4 after the initial injection in the FTP. Percent change from Baseline in the strabismus angle was calculated as: absolute angle ([strabismus angle at Baseline minus strabismus angle after the final injection] divided by the absolute strabismus angle at Baseline) multiplied by 100.

  • Percent Change From Baseline in the Strabismus Angle in the Primary Position at Weeks 1, 4, 8, 12, 16, 20, and 24 After the Final Injection of the FTP [ Time Frame: Baseline and Weeks 1, 4, 8, 12, 16, 20, and 24 of the FTP ] [ Designated as safety issue: No ]
    The strabismus angle in the primary position was measured using the APCT. The strabismus angle was evaluated as the mean value of the distant-view strabismus angle (measured at a distance of 5 m) and the near-view strabismus angle (measured at a distance of 33 cm). Every participant's evaluation was performed in the same affected eye (left or right) throughout the study period. The values were summarized for observed cases for the percent change from Baseline in the strabismus angle in the primary position at Weeks 1, 4, 8, 12, 16, 20, and 24 (before reinjection of the second treatment period if applicable) after the final injection of the FTP (after randomization in the non-treatment groups; up to a maximum of 52 weeks of the FTP). Percent change from Baseline in the strabismus angle was calculated as: (absolute angle [strabismus angle at Baseline minus the strabismus angle after the final injection] divided by the absolute strabismus angle at Baseline) multiplied by 100.

  • Percent Change From Baseline in the Strabismus Angle in the Primary Position at Weeks 1, 4, 8, 12, 16, 20, and 24 of the STP [ Time Frame: Baseline and Weeks 1, 4, 8, 12, 16, 20, and 24 of the STP (up to Study Week 52) ] [ Designated as safety issue: No ]
    The strabismus angle in the primary position was measured using the APCT. The strabismus angle was evaluated as the mean value of the distant-view strabismus angle (measured at a distance of 5 m) and the near-view strabismus angle (measured at a distance of 33 cm). Every participant's evaluation was performed in the same affected eye (left or right) throughout the study period. Percent change from Baseline in the strabismus angle was calculated as: (absolute angle [strabismus angle at Baseline minus the strabismus angle after the final injection] divided by the absolute strabismus angle at Baseline) multiplied by 100.

  • Duration of Effect [ Time Frame: Up to Week 48 after the final injection of the FTP (up to Study Week 52) ] [ Designated as safety issue: No ]
    Duration of effect is defined as the number of days after the final injection of the FTP (after randomization in the non-treatment groups) until the date of the first recording of a value smaller than 50% in percent correction compared to the maximum change in the strabismus angle in the primary position. The strabismus angle in the primary position was measured using the APCT. The strabismus angle was evaluated as the mean value of the distant-view strabismus angle (measured at a distance of 5 m) and the near-view strabismus angle (measured at a distance of 33 cm). Percent correction compared to the maximum change in the strabismus angle was calculated as: (absolute angle [strabismus angle at Baseline minus the strabismus angle after injection]/absolute angle [strabismus angle at Baseline minus the strabismus angle at maximum change]) multiplied by 100.

  • Severity of Duction Limitation at Weeks 1 and 4 of the FTP [ Time Frame: Week 1 and Week 4 of the FTP ] [ Designated as safety issue: No ]
    The severity of duction limitation was calculated for participants with paralytic strabismus. For each evaluable participant, assessment was done by taking a frontal photo of the condition of the affected eye to determine the maximum movement toward the direction to which duction is limited while the non-affected eye was masked with eye-patch. The evaluation was performed in the same eye (left or right) throughout the study period. Based on the photos, the severity of the duction limitation was assessed on a 6-point scale, with scores ranging from 0=no duction limitation to -5=cannot rotate eye to midline.

  • Severity of Duction Limitation at Weeks 1, 4, 8, 12, 16, 20, and 24 After the Final Injection of the FTP [ Time Frame: Weeks 1, 4, 8, 12, 16, 20, and 24 after the final injection of the FTP (up to a maximum of 52 weeks of the FTP) ] [ Designated as safety issue: No ]
    The severity of duction limitation was calculated for participants with paralytic strabismus. For each evaluable participant, assessment was done by taking a frontal photo of the condition of the affected eye to determine the maximum movement toward the direction to which duction is limited while the non-affected eye was masked with eye-patch. The evaluation was performed in the same eye (left or right) throughout the study period. Based on the photos, the severity of the duction limitation was assessed on a 6-point scale, with scores ranging from 0=no duction limitation to -5=cannot rotate eye to midline.

  • Severity of Duction Limitation at Weeks 1, 4, 8, 12, 16, 20, and 24 of the STP [ Time Frame: Weeks 1, 4, 8, 12, 16, 20, and 24 of the STP (up to Study Week 52) ] [ Designated as safety issue: No ]
    The severity of duction limitation was calculated for participants with paralytic strabismus. For each evaluable participant, assessment was done by taking a frontal photo of the condition of the affected eye to determine the maximum movement toward the direction to which duction was limited while the non-affected eye was masked with eye-patch. The evaluation was performed in the same eye (left or right) throughout the study period. Based on the photos, the severity of the duction limitation was assessed on a 6-point scale, with scores ranging from 0=no duction limitation to -5=cannot rotate eye to midline.

  • Change From Baseline in the Severity of Duction Limitation at Weeks 1 and 4 of the FTP [ Time Frame: Baseline and Weeks 1 and 4 of the FTP ] [ Designated as safety issue: No ]
    The severity of duction limitation was calculated for participants with paralytic strabismus. For each evaluable participant, assessment was done by taking a frontal photo of the condition of the affected eye to determine the maximum movement toward the direction to which duction was limited while the non-affected eye was masked with eye-patch. The evaluation was performed in the same eye (left or right) throughout the study period. Based on the photos, the severity of the duction limitation was assessed on a 6-point scale, with scores ranging from 0=no duction limitation to -5=cannot rotate eye to midline. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

  • Change From Baseline in the Severity of Duction Limitation at Weeks 1, 4, 8, 12, 16, 20, and 24 After the Final Injection of the FTP [ Time Frame: Baseline and Weeks 1, 4, 8, 12, 16, 20, and 24 after the final injection of the FTP (up to a maximum of 52 weeks of the FTP) ] [ Designated as safety issue: No ]
    The severity of duction limitation was calculated for participants with paralytic strabismus. For each evaluable participant, assessment was done by taking a frontal photo of the condition of the affected eye to determine the maximum movement toward the direction to which duction was limited while the non-affected eye was masked with eye-patch. The evaluation was performed in the same eye (left or right) throughout the study period. Based on the photos, the severity of the duction limitation was assessed on a 6-point scale, with scores ranging from 0=no duction limitation to -5=cannot rotate eye to midline. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

  • Change From Baseline in the Severity of Duction Limitation at Weeks 1, 4, 8, 12, 16, 20, and 24 of the STP [ Time Frame: Baseline and Weeks 1, 4, 8, 12, 16, 20, and 24 of the STP (up to Study Week 52) ] [ Designated as safety issue: No ]
    The severity of duction limitation was calculated for participants with paralytic strabismus. For each evaluable participant, assessment was done by taking a frontal photo of the condition of the affected eye to determine the maximum movement toward the direction to which duction was limited while the non-affected eye was masked with eye-patch. The evaluation was performed in the same eye (left or right) throughout the study period. Based on the photos, the severity of the duction limitation was assessed on a 6-point scale, with scores ranging from 0=no duction limitation to -5=cannot rotate eye to midline. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.


Enrollment: 41
Study Start Date: May 2012
Study Completion Date: June 2014
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Non-treatment (10-20 PD)
Receive no treatment on Week 0
Active Comparator: GSK1358820 1.25 U (10-20 PD)
Receive 1.25 U of GSK1358820 on Week 0
Drug: GSK1358820
IM injection of Botulinum Toxin Type A
Other Name: Botulinum Toxin Type A
Active Comparator: GSK1358820 2.5 U (10-20 PD)
Receive 2.5 U of GSK1358820 on Week 0
Drug: GSK1358820
IM injection of Botulinum Toxin Type A
Other Name: Botulinum Toxin Type A
No Intervention: Non-treatment (20-50 PD)
Receive no treatment on Week 0
Active Comparator: GSK1358820 2.5 U (20-50 PD)
Receive 2.5 U of GSK1358820 on Week 0
Drug: GSK1358820
IM injection of Botulinum Toxin Type A
Other Name: Botulinum Toxin Type A
Active Comparator: GSK1358820 5.0 U (20-50 PD)
Receive 5.0 U of GSK1358820 on Week 0
Drug: GSK1358820
IM injection of Botulinum Toxin Type A
Other Name: Botulinum Toxin Type A

Detailed Description:

Primary objective is to evaluate the efficacy of single-dose treatment with GSK1358820 compared with non-treatment in patients with strabismus based on angles of strabismus in the primary position. Secondary objective is to evaluate the efficacy and safety of repeated-dose treatment with GSK1358820 in patients with strabismus.

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

<At the start of screening period>

  • Paralytic or concomitant strabismus. Subjects with paralytic strabismus will be eligible for inclusion only if paralysis has persisted for at least 3 months and strabismus has been developed at one eye
  • Horizontal deviations (esotropia or exotropia)
  • Strabismus with the (absolute) strabismus angles at both distance and near of primary position >-10 PD and <50 PD
  • Age>-12 years at the time of giving informed consent
  • The subject has to be capable of giving written informed consent of their own will. For subjects aged less than 20 years, the subject and his/her legally acceptable representative (person in parental authority or guardian) have to give written informed consent
  • Either sex. Males have to agree to practice contraception during the study period. Females of child-bearing potential will be eligible for inclusion in this study. However, they have to have negative pregnancy test both at the screening visit and just before initial injection and agree to practice reliable methods of contraception
  • QTc <450 msec; for patients with Bundle Branch Block, QTc <480 msec based on average QTc value of triplicate ECGs <At the start of treatment period >
  • Strabismus with the (absolute) strabismus angles at both distance and near of primary position >-10 PD and <50 PD
  • ALT at the screening visit <2 x ULN and alkaline phosphatase and bilirubin <-1.5 x ULN

Exclusion Criteria:

<At the start of screening period>

  • Secondary strabismus caused by prior surgical recession of the antagonist in past surgical treatment of strabismus
  • Strabismus due to abnormal innervations
  • Strabismus with thyroid-associated ophthalmopathy
  • Strabismus with strong motor limitation of extraocular muscles
  • Mechanical limitations of ocular movement due to periorbital disease or due to past surgical treatment other than strabismus
  • Blepharoptosis
  • Conjunctival pathology
  • Systemic neuromuscular junction dysfunction
  • Systemic neuromuscular disease
  • Past treatment with botulinum toxin
  • Planned injections of botulinum toxin for other indication(s) or for cosmetic purpose during the study period
  • Known hypersensitivity to any of the drugs to be used in the study or history of allergy
  • Treatment with antibiotics with neuromuscular junction inhibitory action such as aminoglycosides, polypeptides, tetracyclines and lincomycins, except those contained in topical antibacterial formulations
  • Treatment with muscle relaxants or drugs with muscle relaxant action
  • Chronic respiratory disorder
  • Severe muscle weakness or atrophy
  • Angle-closure glaucoma or its predisposing factors
  • Severe cardiac, hepatic or renal impairment. The severity refers to Grade 3 according to "the Classification of the Severity of Adverse Experiences" (MHLW PAB/SD Notification No. 80, dated 29 June 1992).
  • Surgical operation or hospitalization to be needed during the study period
  • Female subjects who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study period
  • Participation in another clinical study within 6 months prior to enrollment in this study or planned participation in another clinical study after enrollment in this study
  • Psychiatric disorder or impairment of intellectual function that may affect the subject's ability to give informed consent or to comply with the trial procedures
  • History of alcohol dependence or drug abuse
  • Subjects whom the investigator (or sub-investigator) considers ineligible for the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01584843

Locations
Japan
GSK Investigational Site
Aichi, Japan, 494-0001
GSK Investigational Site
Fukuoka, Japan, 812-0011
GSK Investigational Site
Hyogo, Japan, 663-8501
GSK Investigational Site
Kagoshima, Japan, 890-0046
GSK Investigational Site
Kanagawa, Japan, 252-0375
GSK Investigational Site
Miyazaki, Japan, 885-0051
GSK Investigational Site
Miyazaki, Japan, 880-0035
GSK Investigational Site
Osaka, Japan, 535-0021
GSK Investigational Site
Osaka, Japan, 569-8686
GSK Investigational Site
Shizuoka, Japan, 431-3192
GSK Investigational Site
Tokyo, Japan, 101-0062
GSK Investigational Site
Tokyo, Japan, 134-0088
GSK Investigational Site
Yamaguchi, Japan, 750-0061
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01584843     History of Changes
Other Study ID Numbers: 116246
Study First Received: April 23, 2012
Results First Received: June 26, 2014
Last Updated: July 3, 2014
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by GlaxoSmithKline:
Botulinum Toxin Type A
Neuromuscular Agents
Strabismus

Additional relevant MeSH terms:
Strabismus
Ocular Motility Disorders
Cranial Nerve Diseases
Nervous System Diseases
Eye Diseases
Botulinum Toxins, Type A
Neuromuscular Agents
Botulinum Toxins
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 27, 2014